|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Indeed, decreased α1-antitrypsin levels in BEAS-2B cells suggest that exposure to PS-MPs increases the risk for chronic obstructive pulmonary disease, and high concentrations of PS-MPs can induce these adverse responses.
|
31727530 |
2020 |
|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COPD subjects with higher serum alpha-1 antitrypsin levels were associated with a worse systemic inflammation status and higher 10-year mortality.
|
31849461 |
2019 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Blood monocyte profiles in COPD patients with PiMM and PiZZ α1-antitrypsin.
|
30827477 |
2019 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD.
|
31467115 |
2019 |
|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Its severe form is characterized by very low serum levels of AAT, and it most often affects the lungs (causing early-onset emphysema or chronic obstructive lung disease (COPD)) and/or liver (leading to jaundice and liver cirrhosis in children and adults).
|
30929319 |
2019 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In combination with smoking or other long-term noxious exposures such as occupational dust and fumes, genetic A1AT deficiency can cause chronic obstructive pulmonary disease, a condition with elevated cardiovascular risk.
|
29432934 |
2018 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
While the most common is AAT deficiency, a genetic disorder associated with chronic obstructive pulmonary disease, additional disorders associated with AAT abnormalities are increasingly recognised.
|
29592975 |
2018 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SERPINA1 Hepatocyte-Specific Promoter Polymorphism Associate with Chronic Obstructive Pulmonary Disease in a Study of Kashmiri Ancestry Individuals.
|
29804144 |
2018 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We aimed to explore the associations of rs9944155AG, rs1051052AG, and rs1243166AG polymorphisms in the Alpha-1-AT gene with the risk of COPD in Uygur population in the Kashgar region.
|
29521291 |
2018 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alpha 1-antitrypsin deficiency (AATD) is a genetic disorder which reduces serum alpha 1-antitrypsin (AAT or alpha1-proteinase inhibitor, A1PI) and increases the risk of chronic obstructive pulmonary disease (COPD).
|
29616482 |
2018 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alpha-1 antitrypsin (AAT) deficiency is associated with an increased risk of chronic obstructive pulmonary disease and has been related to CD4 T-cell count decline in people living with HIV (PLWH).
|
30160349 |
2018 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Beside the well-known proteinase inhibitory function, which protects the lungs from chronic obstructive pulmonary disease (COPD), many studies have shown that AAT inhibits pro-inflammatory cytokine gene expression and functions.
|
30194599 |
2018 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WGS in severe COPD identifies a large number of potentially important functional variants, with the strongest associations being in known COPD risk loci, including HHIP and SERPINA1.
|
29949718 |
2018 |
|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The objectives of this study were to assess the frequency and determinants of testing serum α1-antitrypsin (AAT) levels in COPD patients, and to describe factors associated with testing.
|
29953442 |
2018 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.
|
28416015 |
2017 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Whether the heterozygous PiMZ genotype for alpha-1 antitrypsin confers increased risk for COPD has been debated.
|
28380308 |
2017 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
In a large genetic association analysis, we identified associations with severe COPD near PPIC and SERPINA1.
|
28170284 |
2017 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of PI*S and PI*Z SERPINA1 alleles in healthy individuals and COPD patients in Saudi Arabia: A case-control study.
|
29049242 |
2017 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alpha-1 antitrypsin (AAT) functions primarily to inhibit neutrophil elastase, and its deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD).
|
28769553 |
2017 |
|
SERPINA1
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To determine the prevalence of alpha 1-antitrypsin (AAT) deficiency (AATD), as well as allele frequency, in COPD patients in Brazil.
|
27812629 |
2017 |
|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This extract induced severe oxidative stress that increased DNA damage and the production of proinflammatory cytokines by BEAS-2B cells as well as decreased α1-antitrypsin expression, suggesting a mechanism that increases the risk of COPD.
|
27614859 |
2017 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Urine samples from 19 clinically stable COPD cases (7 PiMM and 12 PiZZ A1AT) were analyzed by capillary electrophoresis coupled to mass spectrometry.
|
28331304 |
2017 |
|
SERPINA1
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Testing for AATD should be part of the reflex testing that follows any COPD diagnosis or unexplained liver disease and can be performed by determining the AAT phenotype or genotype along with serum AAT levels.
|
28929906 |
2017 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment of A1ATD-associated lung disease includes standard therapies that are also used for the treatment of COPD, in addition to the use of augmentation therapy (that is, infusions of human plasma-derived, purified α1-antitrypsin).
|
27465791 |
2016 |
|
SERPINA1
|
0.500 |
Biomarker
|
disease |
BEFREE |
The loss of anti-inflammatory and antiproteolytic functions, together with pro-inflammatory effects of polymerized AAT contribute to protein degradation and increased inflammation resulting in an increased risk of developing chronic obstructive pulmonary disease (COPD) and emphysema, especially in smokers.
|
26341117 |
2016 |